The Treatments Dashboard provides a comprehensive overview of therapeutic approaches and treatment coverage in NeuroWiki. This page serves as a central navigation hub for finding treatment information by disease, mechanism, and development stage.
| Metric | Value |
|--------|-------|
| Total Treatment Pages | 538 |
| Alzheimer's Treatments | ~120 |
| Parkinson's Treatments | ~100 |
| ALS Treatments | ~80 |
| Approved Therapies | ~45 |
| Clinical Trial Candidates | ~200 |
| Phase |
Count |
Success Rate |
| Phase 3 |
35 |
18% |
| Phase 2 |
65 |
28% |
| Phase 1 |
80 |
35% |
| Phase |
Count |
Success Rate |
| Phase 3 |
25 |
22% |
| Phase 2 |
50 |
30% |
| Phase 1 |
65 |
38% |
| Phase |
Count |
Success Rate |
| Phase 3 |
15 |
12% |
| Phase 2 |
25 |
25% |
| Phase 1 |
35 |
32% |
| Drug |
Company |
Indication |
Approval Year |
| Leqembi |
Eisai/Biogen |
AD |
2023 |
| Kisunla |
Eli Lilly |
AD |
2024 |
| Rytary |
AbbVie |
PD |
2015 |
| Radicut |
Mitsubishi |
ALS |
2017 |
| Exserv |
MT Pharma |
ALS |
2017 |
| Mechanism |
Active Trials |
Promise Level |
| Amyloid Clearance |
45 |
High |
| Tau Propagation Blockers |
38 |
High |
| Alpha-Synuclein Aggregation |
28 |
High |
| LRRK2 Inhibition |
22 |
Medium-High |
| Neuroinflammation |
42 |
Medium-High |
| Metabolic Support |
30 |
Medium |
Last updated: 2026-03-17